Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 3/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24045753 | 1.00 | GPR84 (0.42) | GPR84FFAR4FFAR1PLA2G1BPLA2G2A | |
| SCHEMBL25955602 | 1.00 | GPR84 (0.42) | GPR84FFAR4FFAR1PLA2G1BPLA2G2A | |
| SCHEMBL10571376 | 0.93 | PLA2G1B (0.43) | GPR84FFAR4FFAR1PLA2G1BPLA2G2A | |
| SCHEMBL19632306 | 0.92 | L3MBTL1 (0.38) | GPR84FFAR4FFAR1PLA2G1BPLA2G2A | |
| SCHEMBL13964584 | 0.92 | L3MBTL1 (0.38) | GPR84FFAR4FFAR1PLA2G1BPLA2G2A | |
| SCHEMBL13964581 | 0.92 | L3MBTL1 (0.38) | GPR84FFAR4FFAR1PLA2G1BPLA2G2A | |
| SCHEMBL13964580 | 0.92 | L3MBTL1 (0.38) | GPR84FFAR4FFAR1PLA2G1BPLA2G2A | |
| SCHEMBL13964583 | 0.92 | L3MBTL1 (0.38) | GPR84FFAR4FFAR1PLA2G1BPLA2G2A | |
| SCHEMBL13829037 | 0.90 | GPR84 (0.40) | GPR84FFAR4FFAR1PLA2G1BPLA2G2A | |
| SCHEMBL12515783 | 0.90 | GPR84 (0.40) | GPR84FFAR4FFAR1PLA2G1BPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302146-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CureVac SE (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20230302146-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CureVac SE (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20230181713-A1 | LASSA VIRUS VACCINE | CureVac SE (DE) | 2023-06-15 | — | — | US | disclosed |
| US-11524066-B2 | Henipavirus vaccine | CureVac SE (DE) | 2022-12-13 | — | — | US | disclosed |
| US-20210401971-A1 | MERS CORONAVIRUS VACCINE | CUREVAC AG (DE) | 2021-12-30 | — | — | US | disclosed |
| US-20210361761-A1 | NOVEL YELLOW FEVER NUCLEIC ACID MOLECULES FOR VACCINATION | CUREVAC AG (DE) | 2021-11-25 | — | — | US | disclosed |
| US-11141476-B2 | MERS coronavirus vaccine | CUREVAC AG (DE) | 2021-10-12 | — | — | US | disclosed |
| US-20210170017-A1 | NOVEL RSV RNA MOLECULES AND COMPOSITIONS FOR VACCINATION | CUREVAC AG (DE) | 2021-06-10 | — | — | US | disclosed |
| US-20210069315-A1 | FLAVIVIRUS VACCINE | CureVac SE (DE) | 2021-03-11 | — | — | US | disclosed |
| US-20210030864-A1 | BUNYAVIRALES VACCINE | CureVac SE (DE) | 2021-02-04 | — | — | US | disclosed |
| US-20200179526-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CureVac SE (DE) | 2020-06-11 | — | — | US | disclosed |
| US-20190351044-A1 | LASSA VIRUS VACCINE | CureVac SE (DE) | 2019-11-21 | — | — | US | disclosed |
| US-20190351047-A1 | HENIPAVIRUS VACCINE | CureVac SE (DE) | 2019-11-21 | — | — | US | disclosed |
| US-20190351048-A1 | MERS CORONAVIRUS VACCINE | CureVac SE (DE) | 2019-11-21 | — | — | US | disclosed |
| US-20190336608-A1 | CATIONIC CARRIERS FOR NUCLEIC ACID DELIVERY | CUREVAC AG (DE) | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190351044-A1 | LASSA VIRUS VACCINE | LASP1, LAS1L, LTA | GPR84 3725/4885FFAR4 3157/4885FFAR1 3048/4885 |
| US-20190336608-A1 | CATIONIC CARRIERS FOR NUCLEIC ACID DELIVERY | HNRNPH3, CHMP4B, HNRNPH1 | GPR84 3098/4885FFAR4 871/4885FFAR1 1311/4885 |
| US-20190351047-A1 | HENIPAVIRUS VACCINE | NIPSNAP3A, NIPSNAP1, DHX35 | GPR84 997/4885FFAR4 4503/4885FFAR1 4186/4885 |
| US-20210030864-A1 | BUNYAVIRALES VACCINE | RNGTT, CHIA, TRMT1 | GPR84 3353/4885FFAR4 3812/4885FFAR1 4054/4885 |
| US-20200179526-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | HNRNPH1, HNRNPH3, SNRPE | GPR84 2607/4885FFAR4 3141/4885FFAR1 3471/4885 |
| US-20210361761-A1 | NOVEL YELLOW FEVER NUCLEIC ACID MOLECULES FOR VACCINATION | VIM, VARS1, ZFR | GPR84 3666/4885FFAR4 4627/4885FFAR1 4702/4885 |
| US-20190351048-A1 | MERS CORONAVIRUS VACCINE | SARS1, RNMT, ACE2 | GPR84 1982/4885FFAR4 3611/4885FFAR1 3367/4885 |
| US-11141476-B2 | MERS coronavirus vaccine | SARS1, RNMT, ACE2 | GPR84 1982/4885FFAR4 3611/4885FFAR1 3367/4885 |
| US-20210170017-A1 | NOVEL RSV RNA MOLECULES AND COMPOSITIONS FOR VACCINATION | RNASEH1, EXOSC9, SYNCRIP | GPR84 672/4885FFAR4 4037/4885FFAR1 3452/4885 |
| US-20230181713-A1 | LASSA VIRUS VACCINE | LASP1, LAS1L, LTA | GPR84 3663/4885FFAR4 3169/4885FFAR1 3044/4885 |
| US-20230302146-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | HNRNPH1, HNRNPH3, SNRPE | GPR84 2607/4885FFAR4 3141/4885FFAR1 3471/4885 |
| US-20210069315-A1 | FLAVIVIRUS VACCINE | TLR9, DDX5, CHIA | GPR84 722/4885FFAR4 4066/4885FFAR1 4086/4885 |
| US-20210401971-A1 | MERS CORONAVIRUS VACCINE | SARS1, RNMT, ACE2 | GPR84 1982/4885FFAR4 3611/4885FFAR1 3367/4885 |
| US-11524066-B2 | Henipavirus vaccine | NIPSNAP3A, NIPSNAP1, DHX35 | GPR84 997/4885FFAR4 4503/4885FFAR1 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.